Mechanism of tyrosine kinase 2 inhibitors in treatment of plaque psoriasis and their progress in clinical trials
10.12092/j.issn.1009-2501.2023.03.011
- Author:
Jiaqing SHEN
1
;
Yi LIU
1
Author Information
1. Hospital of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
- Publication Type:Journal Article
- Keywords:
JAK-STAT pathway;
plaque psoriasis;
tyrosine kinase 2 inhibitor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(3):323-330
- CountryChina
- Language:Chinese
-
Abstract:
As a chronic, immune-mediated inflammatory disease, plaque psoriasis has a great burden of disease and influences on patient's physical and mental health. In the past decade, plaque psoriasis treatment with biological agents achieved breakthrough development, while oral drugs with promising efficacy and safety are yet to be met. By cell signal transduction, the Janus kinase-signal transducer and activator of transcription pathway plays an important role in numerous immune-related diseases. Tyrosine kinase 2 (TYK2), a member of the JAK family, can impact on plaque psoriasis by regulating signaling and functional responses downstream of IL-12, IL-23, IFN. Deucravacitinib, a highly selective TYK2 inhibitor, has finished its phase 3 clinical trials and shown its efficacy and safety in treatment of plaque psoriasis. Several kinds of TYK2 inhibitors are under research and development at the moment. In this review, we demonstrate roles of JAK-STAT pathway and TYK2 in plaque psoriasis as well as updates on ongoing and recently completed trials of TYK2 inhibitors.
